European life sciences investor BioMedPartners has held its first closing of BioMedInvest II, the company’s second venture capital fund, at CHF95m (€64m).
BioMedInvest II is a healthcare-dedicated fund which invests in early to mid-stage companies in Switzerland, Germany and neighbouring countries of the European Union.
The fund is backed by both existing and new investors, including the lead investor ERP-EIF Dachfonds. The fund will remain open for additional new investors for some months.
The management team of BioMedPartners said of the close: “The fact that BioMedPartners was able to raise a new early-stage fund in such turbulent times encourages the management team to continue with its favourable business model by investing in promising early-stage healthcare companies in Europe and by actively supporting companies in their business/corporate development.”
Fund II is the first fund raised by BioMedPartners since 2003 when it raised Fund I, a healthcare VC fund, which closed on CHF100m.